

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

## **OTHER RELEVANT INFORMATION**

As a continuation of the communications filed last week by the Company as a consequence of the report from the short seller investor Grifols wants to inform the following:

In light of the concerns brought forward by the markets regarding on how the report could influence in the transaction of the sale of 20% of Shanghai RAAS Blood Products Co., Ltd. and having been in contact with the buyer, Haier Group Corporation, Grifols wants to inform that the Vice-Chairperson of Haier Group Corporation has textually declared the following: "*we continue to work to close the deal as originally planned*".

The transaction continues to progress as planned and Grifols expects to close this transaction during the first half of FY 2024, as has already been communicated to the market.

In Barcelona, on January 14, 2024

---

Nuria Martín Barnés  
Secretary of the Board of Directors